drugset
drugset / Trial / NCT07203352

Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL

NCT07203352 ↗

Phase 3 Recruiting 154 enrolled Nanfang Hospital, Southern Medical University
RandomizedParallel-groupOpen-labelTreatment

Summary

This prospective, randomized, controlled trial evaluates the efficacy and safety of a new targeted drug combined with chemotherapy versus standard chemotherapy alone. Eligible patients were randomized 1:1 to either the treatment or control group.

Timeline

Start
2025-10-01
Primary completion
2026-12-01
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule 400 mg Oral
Subject dasatinib anhydrous Small molecule 100 mg Oral

Indications

acute lymphoblastic leukemia